Physician profile
Isaac Tafur
NPI 1679536387
$2,302.06
in general payments reported to CMS, 2019-2025
33 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $118 · 2021: $139 · 2022: $11.97 · 2023: $96.84 · 2024: $472 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121 · Education: $83.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.42 |
| Education | $83.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $402.40 | 2019-2025 | |
| Janssen Biotech, INC. | $232.44 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $221.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.40 | 2019-2025 | Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $118.75 | 2019-2025 | Keytruda |
| Genentech USA, INC. | $113.45 | 2019-2025 | Lunsumio, Polivy, Columvi |
| Jazz Pharmaceuticals INC. | $111.88 | 2019-2025 | |
| Amgen INC. | $111.71 | 2019-2024 | Imdelltra (Amg 757) |
| Abbvie INC. | $102.38 | 2019-2025 | |
| Seagen INC. | $76.27 | 2019-2021 | |
| Celgene Corporation | $72.87 | 2024-2025 | Reblozyl |
| Incyte Corporation | $71.08 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $61.18 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $48.63 | 2024-2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $41.44 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.90 | 2019 | |
| Gilead Sciences, INC. | $33.24 | 2019-2021 | |
| Astellas Pharma US INC | $30.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.04 | 2019 | |
| Adaptive Biotechnologies Corporation | $27.92 | 2024 | Clonoseq |
| Array Biopharma INC | $26.28 | 2025 | Braftovi, Lorbrena, Mektovi |
| Ipsen Biopharmaceuticals, INC | $24.03 | 2025 | Onivyde |
| Genzyme Corporation | $23.47 | 2019 | |
| Genmab U.S., INC. | $21.89 | 2024 | Epkinly |
| Dova Pharmaceuticals | $17.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2019 | |
| Lilly USA, LLC | $15.88 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.05 | 2019 | |
| Eisai INC. | $12.23 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Tafur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.